NCT04743518

Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Centre Hospitalier Universitaire, Amiens · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An increased risk of cardiovascular (CV) diseases has been observed in patients with inflammatory bowel diseases (IBD). The impact of IBD drugs, such as anti-TNF, anti-integrins or anti-JAK, on the risk of CV events in IBD is remains unknown. Aortic pulse wave velocity (aPWV), a measure of aortic stiffness, and carotid intima media thickness (CIMT) are both predictors of cardiovascular events and are increased in patients with IBD. The investigators aimed to prospectively compare the CV risk, CIMT, arterial stiffness and biomarkers of endothelial dysfunction at baseline and after 3 and 12 months of anti-TNF, vedolizumab and tofacitinib.

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
OTHER	Aortic pulse wave velocity	Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
OTHER	carotid intima media thickness (CIMT)	carotid intima media thickness (CIMT)

Timeline

• Start date: 2021-02-02
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2021-02-08
• Last updated: 2025-05-29

Locations

1 site across 1 country: France